As we noted earlier today Sanofi (NYSE: SNY) received FDA approval for Admelog, their biosimilar short-acting insulin. A move which will just push all the insulin makers into the device world, somewhere Lilly (NYSE: LLY) has been very public about and somewhere Novo Nordisk (NYSE: NVO) will likely follow. We also believe that Medtronic (NYSE: MDT) will go in the opposite direction and get into the insulin business albeit not directly but via a third party.
As we have noted the insulin companies don’t see devices as a profit center per see, rather as an attempt to change . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.